Why BGPT?
logo

The Evidence Layer for Scientific AI

Ask questions across claims linked to experiments, exact results, limitations, and sources.Know what falsifiable science actually supports before you trust the answer.

Press Enter ↡ to search evidence


     Quick Explanation



    This 1957 Lancet report documents two uncontrolled cases in which intravenous L-noradrenaline rapidly restored systolic pressure (~130 mm Hg) and was followed by return of urine output, with no observed renal or infusion complications . With n=2, no controls, and confounding resuscitative therapy, it is hypothesis-generating historical evidence only, not proof of renal benefit .


     Long Explanation



    What the paper reports

    This 1957 Lancet case series describes two patients: a 63-year-old woman who developed anuric acute renal failure after vaginal hysterectomy, complicated by profuse diarrhoea and staphylococcal enteritis, with unrecordable blood pressure resistant to methylamphetamine; and a 49-year-old man in diabetic ketosis who became oliguric and pulseless with a blood-urea of 160 mg/100 ml. In both, an intravenous L-noradrenaline ('Levophed') infusion rapidly raised systolic pressure to ~130 mm Hg β€” Case 1 requiring initially ~40 Β΅g/min, peaking at 73 Β΅g/min, then tapering to 4 Β΅g/min before cessation at 86 hours without side-effects . Case 2 received ~20 Β΅g/min with an immediate pressure rise and increased urine output. Diuresis in Case 1 started on day 11 of severe oliguria.

    Core clinical tension

    The authors confront the physiological objection directly: Nickel et al. and Lathem showed noradrenaline reduces renal blood-flow while raising urine output in normals and chronic renal disease, implying intrarenal vasoconstriction and relative tubular ischaemia . Their counterargument β€” that restoring systemic pressure increases renal perfusion and outweighs local vasoconstriction β€” is biologically plausible but empirically untested here; the authors themselves state it is impossible to prove noradrenaline had no deleterious renal effect .

    Practical contributions

    The paper's most durable value is operational: a dosage philosophy (titrate to systolic ~130 mm Hg; typical initial range 10–30 Β΅g/min; double or treble concentration rather than drip-rate in anuric patients to avoid over-hydration), a dosing chart relating drip-rate to drug concentration, and a venous necrosis-avoidance technique (deep Polythene cannulation of an ankle vein for >80 hours, watching for skin bluish discoloration) .

    Critical appraisal

    • Causation cannot be assigned: recovery followed combined resuscitation β€” blood, plasma, saline, insulin, fluids, erythromycin β€” making noradrenaline's specific renal contribution unmeasurable.
    • n=2, no controls, no randomization; the authors note only that a similar diuresis followed noradrenaline in two barbiturate-poisoning cases, i.e., anecdote-stacking, not evidence.
    • Selection/positive-result bias: failures and adverse outcomes were not systematically reported; only 'excessive sweating' at high doses and one episode of perivascular leakage are mentioned.
    • No long-term renal follow-up: Case 1 had persistent proteinuria for weeks with no formal renal function testing reported β€” an unexamined possible iatrogenic signal .
    • Dose targets are outdated: targeting 130 mm Hg systolic and doses up to 150 Β΅g/min reflect 1950s practice, not modern goal-directed vasopressor therapy.

    What would change the conclusion

    Modern nephrology's dominant framing β€” vasopressor support via norepinephrine in shock with careful perfusion targets β€” retrospectively vindicates the direction of the authors' conjecture, but properly controlled trials, not these cases, established it. The paper's claims would be falsified by showing that normotensive restoration without noradrenaline fails to restore urine output in oliguric shock, or that higher rates of renal non-recovery follow norepinephrine versus other vasopressors in randomized settings. Neither test was possible in 1957, and this paper makes no attempt at either β€” which is exactly why it should be read as a hypothesis source, not evidence.



    Feedback:    

    Updated: November 17, 2026



     BGPT Paper Review



    Study Novelty

    50%

    For 1957, questioning whether noradrenaline was nephrotoxic in oliguric shock was timely; today the question and answer are historically settled.



    Scientific Quality

    30%

    Two uncontrolled case reports with confounded co-therapies, no renal function testing, and admitted inability to exclude harm; intellectually honest but weak evidence.



    Study Generality

    40%

    Raises a genuinely general question β€” perfusion restoration vs vasoconstriction in shock kidney β€” but draws conclusions from a population of two.



    Study Usefulness

    40%

    Concrete titration, concentration-vs-drip-rate, and infusion-site practical guidance retain some historical/practical value despite obsolete targets.



    Study Reproducibility

    20%

    Case-report format with adequate lab methodology but no protocol, dataset, or analytic plan; effectively not reproducible as a study.



    Explanatory Depth

    40%

    Mechanistic reasoning is stated (intrarenal vasoconstriction vs systemic perfusion) but never tested or quantified.


    🎁 Authors: Collect 3 Free Science Tokens (β‰ˆ $0.3 USD)

    Claim My Author Tokens

    Use for 0 days of free BGPT access (4 tokens = 1 day) or trade/sell (β‰ˆ $0.3 USD)

     Top Data Sources ExportMCP



     Hypothesis Graveyard



    Methylamphetamine as an alternative vasopressor: abandoned because it raises cardiac output while lowering peripheral resistance, useless in peripheral circulatory failure.


    Fixed-dilution noradrenaline protocols (e.g., 6-8 Β΅g/min in 1.5-2 ml/min): superseded because fluid-restricted anuric patients required concentrated solutions to avoid over-hydration.

     Science Art


    Paper Review: L-NORADRENALINE THERAPY IN ACUTE RENAL FAILURE Science Art

     Science Movie



    Make a narrated HD Science movie for this answer ($64 per minute)




     Discussion


    Stay current without chasing every paper.

    Know what changed, what holds up, and what remains uncertain. Every Friday. No ads.


    My BGPT